Home » Stocks » IOVA

Iovance Biotherapeutics, Inc. (IOVA)

Stock Price: $50.93 USD -0.13 (-0.25%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Pre-market: $51.00 +0.07 (0.14%) Jan 20, 6:41 AM
Market Cap 7.48B
Revenue (ttm) n/a
Net Income (ttm) -254.75M
Shares Out 146.49M
EPS (ttm) -1.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $50.93
Previous Close $51.06
Change ($) -0.13
Change (%) -0.25%
Day's Open 52.00
Day's Range 50.43 - 53.01
Day's Volume 1,017,529
52-Week Range 19.54 - 53.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 22 hours ago

SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

Seeking Alpha - 3 weeks ago

Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifile...

GlobeNewsWire - 3 weeks ago

SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

GlobeNewsWire - 1 month ago

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

Zacks Investment Research - 1 month ago

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 month ago

SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

Zacks Investment Research - 2 months ago

Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

GlobeNewsWire - 2 months ago

44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up

Seeking Alpha - 2 months ago

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

SAN CARLOS, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, wil...

Insider Monkey - 2 months ago

In this article we are going to use hedge fund sentiment as a tool and determine whether Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a good investment right now. We like to analyze hedge fu...

GlobeNewsWire - 2 months ago

SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

Seeking Alpha - 2 months ago

Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to m...

GuruFocus - 2 months ago

Smaller biotechs would make nice additions to pharma companies in similar areas of therapy

Other stocks mentioned: GBT, RETA
GlobeNewsWire - 3 months ago

SAN CARLOS, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

PRNewsWire - 3 months ago

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors...

Zacks Investment Research - 3 months ago

Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.

Market Watch - 3 months ago

Shares of Iovance Biotherapeutics Inc. iova were down 20.0% in premarket trading on Tuesday, the day after the biotechnology company said it plans to now submit an application to the Food and ...

GlobeNewsWire - 3 months ago

SAN CARLOS, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

GlobeNewsWire - 3 months ago

SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...

Zacks Investment Research - 4 months ago

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 5 months ago

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

GlobeNewsWire - 5 months ago

SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, t...

Seeking Alpha - 5 months ago

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study

GlobeNewsWire - 5 months ago

SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, w...

Kiplinger - 6 months ago

The pandemic has put the health care industry under a global spotlight.

Other stocks mentioned: AMGN, ANTM, BMY, GH, IQV, MDT, VEEV, WST, XLRN
The Motley Fool - 6 months ago

After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.

Seeking Alpha - 6 months ago

Adding One More Dimension In Solid Tumor Therapy - Iovance Biotherapeutics

GlobeNewsWire - 7 months ago

SAN CARLOS, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, t...

Zacks Investment Research - 7 months ago

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 7 months ago

Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock Offering Includes Exercise in Full of the Underwriters’ Option to Pu...

Zacks Investment Research - 7 months ago

Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 7 months ago

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up

GlobeNewsWire - 7 months ago

SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based ca...

The Motley Fool - 7 months ago

The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.

Benzinga - 7 months ago

Iovance Biotherapeutics (NASDA:IOVA) shares are trading lower on Thursday, after the company announced a $500 million proposed public offering of common stock.

Investors Business Daily - 7 months ago

Iovance unveiled promising test results for a cancer treatment, but IOVA stock tumbled Thursday on a subsequent public offering. Proceeds will be used, in part, to launch the drug.

GlobeNewsWire - 7 months ago

SAN CARLOS, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based c...

GlobeNewsWire - 7 months ago

Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up

GlobeNewsWire - 8 months ago

Median Duration of Response Not Reached at 17.0 Months  of Median Study Follow Up in C-144-01 Study

InvestorPlace - 8 months ago

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

Other stocks mentioned: ARGX, ASND, AXSM, FOLD, NTRA, UTHR
Zacks Investment Research - 8 months ago

Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

Seeking Alpha - 8 months ago

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2020 Results - Earnings Call Transcript

GuruFocus - 8 months ago

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) might be even more attractive to rumored suitors after the San Francisco-area company’s cancer-fighting treatment showed promise in early testing.

Other stocks mentioned: GILD, TAK
Zacks Investment Research - 9 months ago

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

The Motley Fool - 9 months ago

The worst is yet to come for the stock market, but these biopharma companies have promising potential.

Other stocks mentioned: FATE
Seeking Alpha - 10 months ago

Iovance Biotheraputics: Still Well-Poised To Treat Solid Tumors

Seeking Alpha - 10 months ago

Iovance Biotherapeutics: Buy The Dip

Zacks Investment Research - 10 months ago

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

About IOVA

Iovance Biotherapeutics, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcin... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Maria Fardis
Employees
148
Stock Exchange
NASDAQ
Ticker Symbol
IOVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is 51.45, which is an increase of 1.02% from the latest price.

Price Target
$51.45
(1.02% upside)
Analyst Consensus: Buy